Objective This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve ...

Background Abnormalities of type I interferon signaling and production can initiate lupus development. Disturbances of nucleic acid-sensing molecules triggered autoreactivity in lupus mouse models.

Objective To assess the economic burden of patients with SLE by disease severity in the USA 1 year before and after diagnosis.Methods Patients aged ≥18 years with a first SLE diagnosis (index date) ...

Purpose TLR7 and TLR8 (TLR7/8) are members of the Toll-Like Receptor family that recognize single strand RNA. Activation of TLR7/8 within immune cells elevates pro-inflammatory cytokines and type ...

Patients with antiphospholipid antibodies (aPL) are at increased risk for arterial or venous thrombosis. There is, however, significant heterogeneity among patients according to clinical and ...

Objective BAFF and APRIL signal through TACI, BCMA, and/or BAFF-R, and play important roles in the activation, differentiation, and/or survival of B cells, particularly antibody-secreting cells, as ...

Background Ultraviolet light (UV) is a known trigger of cutaneous lupus erythematosus (CLE) flares in systemic lupus erythematosus (SLE) patients, yet cell populations and mechanisms driving UV- ...

Purpose Tertiary lymphoid structures (TLS) are organized aggregation of immune cells at sites of inflammation. The development of TLS in autoimmune settings indicate that they may be sites for both ...

Results When comparing OT images of a total of 48 PIPs from healthy volunteers and 160 PIPs from SLE patients, an AUC of 0.79 is obtained with corresponding sensitivity and specificity of 77% and 71% ...

Background Lupus nephritis (LN) is a common and severe complication of systemic lupus erythematosus requiring renal biopsy to guide treatment decisions. Despite standard-of-care therapy, a third of ...

Background Belimumab and low dose IL2 (Ld-IL2) has been identified effective in the treatment of systemic lupus erythematosus (SLE). However, the application of combined therapy for SLE has not been ...

Systemic lupus erythematosus (SLE) is the most common form of lupus; however, the development of new drugs for SLE has been limited, with only two drugs approved in the past 60 years. Recently, the ...